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 Novel 1,5-benzothiazepin-4-(5H)-one derivatives (8a-8g) have been synthesized by 
intramolecular cyclization of 6 using propyl phosphonic anhydride (T3P) as a 
cyclodehydrating agent. The anti-angiogenic and anti-oxidant properties of the new derivatives 
were then evaluated. Compounds 8b, 8d, 8e, 8f and 8g exhibited very good inhibition of 
capillary proliferation, thus proving their anti-angiogenic properties. In addition, the in vitro 
antioxidant activities of these compounds were evaluated using diphenyl picryl hydrazine 
(DPPH), OH-, metal ion-chelating and NO (nitric oxide) assays, and the results compared with 
butylated hydroxytoluene (BHT), a well known anti-oxidant. Compounds 8a-8g showed 
excellent free-radical scavenging activities in the metal ion-chelating assay, and compounds 
8f and 8g showed nitric oxide radical scavenging properties at a concentration of 20-100 
µg/mL, and are thus more potent than BHT. 
© 2015Growing Science Ltd.  All rights reserved. 
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1. Introduction 
     Angiogenesis is the development of new blood vessels from pre-existing vasculatures and this has 
been well recognized as an essential hallmark for the growth, invasion and metastasis of tumors.1 
Deregulation of angiogenesis under pathological conditions causes several diseases like diabetic 
retinopathy, rheumatoid arthritis, and cancer.2 Thus, the inhibition of tumor angiogenesis provides a 
therapeutic strategy for treating different types of cancers. In many cases anti-angiogenic agents act as 
cytostatics and prevent the growth of tumors, though it is thought that they can be made more successful 
in cancer chemotherapy by combining with cytotoxic agents.3 
     Antioxidants are molecules inhibiting the oxidation of other molecules thereby preventing the cell 
death that occurs due to the release of free radicals.4 Reactive oxygen species generated in the cell 
during anti-oxidation initiate and promote tumor growth as well as other degenerative diseases such as 
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heart attacks, strokes, arthritis and cataracts.5 Minimizing oxidative damage may be an important 
approach to the primary treatment of these diseases, since antioxidants prevents the free radical 
formation, or interrupt an oxidizing chain reaction. Thus, antioxidants can be regarded as important 
factors for the treatment of cancer. Compounds functioning with groups endowed with potential 
antioxidant properties are considered as new drugs for chemoprevention and chemotherapy.6 Therefore, 
the development of synthetic compounds, capable of scavenging free radicals, has been a great interest. 
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Fig. 1. Examples of 1,5-benzothiazepine drugs  
 
      1,5-Benzothiazepines constitute an important class of privileged scaffolds as a result of their 
immense chemotherapeutic applications, such as calcium channel blockers,7 angiotensin converting 
enzyme inhibitors,8 anticonvulsant,9 anti-HIV,10 anti-hypertensive,11 platelet aggregation inhibitors12 
and cytotoxic13 agents. They have also been reported as potent antibacterial,14 antimicrobial,15 and 
Bradykinin agonists.16 Diltiazem [Fig. 1],17 a well-known angina-relieving calcium channel blocker 
and coronary vasodilator, and Thiazesim,18 used as an antidepressant, and the antipsychotic 
Quetiapine,19 possess 1,5-benzothiazepine skeletons.  
 
Because of their interesting biological properties, functionalized 1,5-benzothiazepin-4(5H)ones 
represent an important class of heterocyclic compounds. The major approaches, for synthesis of 1,5-
benzothiazepinones are cyclization and ring expansion. The most widely employed methods involves, 
nucleophilic attack of substituted 2-aminothiophenols or 2-nitrothiophenols on aliphatic electrophiles20 
and the reaction of 2-fluoronitroarenes with β-mercapto acid, followed by nitro group reduction and 
cyclisation.21 (Scheme 1). 
 
Scheme 1. Synthetic methods for preparation of 1,5-benzothiazepin-4(5H)-ones  
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 In continuation of our work on development of synthetic methodologies for bioactive molecules,22,23 
we report herein an efficient, versatile and convenient synthetic route which provides rapid access to 
1,5-benzothiazepin-4(5H)-ones using a multistep strategy from readily available diethyl di-n-butyl 
malonate 1 and a new coupling agent T3P (Figure 2)  and their anti-angiogenic and anti-oxidant 
properties.  
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Fig. 2. Structure of T3P 
2. Results and discussion 
 
2.1. Chemistry 
 
The synthesis of 1,5-benzothiazepin-4(5H)-one derivatives was accomplished in seven steps as outlined 
in Scheme 2.  
 
(a) DIBAL-H, NaBH4; (b) NaOH, MeOH; (c) HBr, conc. H2SO4; (d) aq. KOH, 4, THF; (e) T3P, 
Et3N; (f) DMF, NaH, RX. 
Scheme 2. Synthetic route of 1,5-benzothiazepin-4(5H)-one derivatives 
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     First, ethyl-[2-n-butyl-2-hydroxymethyl]hexanoate 2 was obtained by selective reduction of diethyl 
di-n-butyl malonate 1 in toluene using DIBAL−H and NaBH4 under N2 atmosphere. Compound ethyl-
(2-n-butyl-2-hydroxymethyl)hexanoic acid 3 was then synthesized in good yield by hydrolysis of ethyl-
(2-n-butyl-2-hydroxymethyl)hexanoate 2 in methanol and NaOH. 2-Bromomethyl-2-n-butylhexanoic 
acid 4 was then obtained by treating ethyl-(2-n-butyl-2-hydroxymethyl)hexanoic acid 3 with 48% (aq.) 
HBr and conc. H2SO4. Amino-6-methoxy benzothiazole 5 in KOH solution was condensed with 2-
bromomethyl-2-n-butylhexanoic acid 4 in THF under N2 atmosphere to yield the desired product, 2-
{[(2-amino-5-methoxyphenyl)thio]methyl}-2-n-butylhexanoic acid 6. Finally, the intramolecular 
cyclization  of 6 using T3P as cyclodehydrating agent afforded the compound 3,3-di-n-butyl-8-
methoxy-2,3-dihydro-1,5-benzothiazepin-4(5H)-one 7. Compounds 8a-8g were obtained in good 
yields (85-92%) by alkylation of 7 with different alkyl halides in DMF using NaH as a base under N2 
atmosphere. We concluded, based on previously published work, that this is the first report in which 
T3P is used as a cyclodehydrating agent in the synthesis of the 1,5-benzothiazepin-4(5H)-one core 
structure 7. The structures of all the synthesized compounds were confirmed by IR, 1H NMR and mass 
spectra.  
 
2.2.Antioxidant activities 
 
2.2.1. DPPH radical scavenging activity 
 
      Antioxidants are characterized by their ability to scavenge free radicals. Proton-radical scavenging 
action is an important attribute of antioxidants, which is measured by DPPH scavenging assay. DPPH, 
a protonated radical has significant absorbance maxima at 517 nm which decreases in the presence of 
antioxidant due to the scavenging of the proton radical24. The hydrogen donating ability of the 
antioxidant molecule contributes to its free radical scavenging potential.  The DPPH radical scavenging 
activity shown by compounds 8a-8g is due to their H-donating capacity. In the present investigation, 
compounds 8a-8g showed low DPPH radical-scavenging activities when compared to BHT (IC50 
values from 136.36 µg/mL to 661.03 µg/mL, BHT has an IC50 value of 10.87 µg/mL). 
 
Hydroxyl radical scavenging activity 
 
       The hydroxyl radical is an extremely reactive free radical formed in biological systems and has 
been implicated as a highly damaging species in free radical pathology as it is capable of damaging 
biomolecules found in living cells.25 Hydroxyl radical has the capacity to cause breakage of DNA, 
which results in cytotoxicity, carcinogenesis and mutagenesis. In addition, this radical species is rapidly 
initiates lipid peroxidation, removing hydrogen atoms from unsaturated fatty-acids.25 In the present 
study, 8a-8g showed moderate hydroxyl radical scavenging activity (8f with IC50 value of 13.64 µg 
and 8b showing 82.94 µg/mL) when compared to standard BHT (IC50 value 10.83 µg/mL). The 
hydrogen-donating capacity of compounds 8a-8g was observed to be moderate compared to BHT as 
shown in Table 1. 
 
Table 1. Free radical scavenging activity of the compounds 8a-8g 
Antioxidant activities    
Compounds  IC50 values (μg/mL)  
 NO Fe2+ OH DPPH 
8a 85.5 97.91 33.56 136.36 
8b 56.40 81.20 82.94 321.43 
8c 56.63 105.60 36.47 473.10 
8d 58.46 39.59 38.61 661.03 
8e 67.42 58.25 30.06 399.61 
8f 35.01 104.69 13.64 429.62 
8g 16.55 96.38 37.64 301.94 
BHT 51.79 213.45 10.83 10.87 
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2.2.2. Nitric oxide radical scavenging activity 
 
      Under physiological conditions, nitric oxide (NO) plays important roles as a neurotransmitter, 
vasodilator and in the immunological system it fights against tumor cells and infectious agents. During 
inflammatory reactions, NO is produced by the inducible enzyme NO synthase (iNOS) in cells like 
macrophages, hepatocytes, and renal cells after stimulation by lipopolysaccharide (LPS), tumor 
necrosis factor (TNF-α), interleukin (IL-1) or interferon (INF-γ), and acts as a defense and regulatory 
signal molecule. However, NO is pathogenic when present in excess, as it is a reactive radical itself, 
and directly damages normal tissues.26 Further, NO can also react with superoxide anion radical to form 
the even stronger oxidant, peroxynitrite.27 Among the samples studied, 8g and 8f showed highly 
significant (P < 0.01) activity in scavenging NO radical with IC50 values of 16.55 and 35.01 µg/mL, 
respectively, when compared to 51.79 µg/mL recorded for BHT (Table 1).  
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Fig. 3. Nitric oxide assay of the synthesized 
compounds 
Fig. 4. Ferrous ion assay of the synthesized 
compounds 
 
2.2.3. Ferrous ion chelating ability 
 
        Iron is known to generate free radicals through the Fenton and Haber-Weiss reactions.28 Metal ion 
chelating activity of an antioxidant molecule prevents oxy-radical generation and consequent oxidative 
damage. Metal ion-chelating capacity plays a significant role in anti-oxidant mechanism since it 
reduces the concentration of the catalyzing transition metal in lipid peroxidation. It is reported that 
chelating agents, which form sigma–bonds with a metal, are effective as secondary antioxidants 
because they decrease the redox potential of the metal centre, thereby stabilizing the oxidized form of 
the metal ion.29 By virtue of both metal chelating properties and radical scavenging ability, compounds 
8a-8g may have a role in the prevention of free radicals with IC50 values ranging from 39.59 µg/mL for 
8d to 105.60 µg/mL for 8c (BHT IC50 value = 213.45 µg/mL).  
 
2.3. Antiangiogenic activity 
 
      Anti-angiogenic treatment is one of the main methods of tumor treatment and control of 
pathological angiogenesis.30 Pathological angiogenesis is regulated by targeting integrins, which are 
predominantly expressed in most of the tumor cells and endothelial cells of blood vessels. The 
interaction of vascular endothelial growth factor (VEGF) and its receptors in a signal transduction 
pathway also regulates angiogenesis.31 
 
      In the present investigation, some of the compounds among 8a-8g reduced the proliferation of blood 
vessels in the shell-less CAM assay model with developing embryos. The proliferation of microvessels 
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was repressed only in group treated with compounds 8b, 8d, 8e, 8f and 8g (Fig. 5) supporting their 
antiangiogenic activity.  
 
   
Control 8b 8d 
   
8e 8f 8g 
 
Fig. 5. Inhibition of angiogenesis in vivo of 1,5-benzothiazepin-4-(5H)-ones (8a–8g) in shell- less CAM 
assay. 
 
3. Conclusion  
 
      In the present study, novel 1,5-benzothiazepin-4(5H)-one derivatives have been synthesized and 
their antioxidant and antiangiogenic activities have been assessed. Oxidative stress and angiogenesis 
are important biological mechanisms by which tumorgenesis and tumor progression occur. Anti-
angiogenic determined in the shell-less CAM model revealed that 8b, 8d, 8e, 8f and 8g compounds are 
endowed with interesting anti-tumor activities. Further, antioxidants have proved to protect against 
oncogenic transformations resulting from radiation and free-radicals in experimental systems.31 The 
significant multiple antioxidant activities of 1,5-benzothiazepin-4(5H)-one derivatives, especially the 
high ferrous ion chelating ability of 8a-8g and nitric oxide radical scavenging activity of 8f and 8g, 
appear to protect the cells by neutralizing or trapping reactive oxygen species and other free radicals. 
These results conclusively prove that rational design of 1,5-benzothiazepin-4(5H)-one derivatives can 
be used to create anti-angiogenic and antioxidant agents.  
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4. Experimental 
 
4.1. General  
 
     All reagents were purchased from Sigma Aldrich Chemicals. Infrared (IR) spectra were recorded 
on a JASCO FT/IR-4100 spectrophotometer in KBr disc for solid compounds and nujol for liquids 
and are reported in reciprocal wave number (cm-1). 1H NMR spectra were recorded in DMSO-d6 at 
300 and 400 MHz. The following abbreviations are used for structural assignments of 1H NMR: s, 
singlet; d, doublet; t, triplet; dd, doublet of doublets; m, multiplet and br, broad. Mass and purity were 
recorded on a LC–MSD-Trap-XCT. Thin layer chromatography was performed using 600 mesh silica 
gel plates, and visualization was effected with short wavelength UV light (254 nm). All other 
commercial reagents were used as received. 
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4.2. General procedure for the synthesis of Ethyl-[2-n-butyl-2-hydroxy methyl]hexanoate (2) 
 
       Diethyl di-n-butyl malonate (25 g, 0.090 mol) was dissolved in toluene (143 mL) under N2 
atmosphere and cooled to -60 to -70 oC. DIBAL-H (25% in toluene, 31.3 g, 0.22 mol) solution was 
added at this temperature over 15 min, then stirred for 4 h. Absolute ethanol (177 mL) was added slowly 
at -40 to -50 oC and the temperature was raised to 0 oC. NaBH4 (3.49 g, 0.090 mol) was added portion-
wise below 0 oC and the reaction mixture was stirred at room temperature for 1 h, cooled to 15–20 oC, 
and saturated Na2SO4 solution was added. The reaction mass was stirred for 1 h, filtered through celite 
bed, extracted with ethyl acetate (25 mL × 2), washed with brine, dried over sodium sulfate and 
concentrated under vacuum at 50-55 oC to afford the title compound 2 as a thick syrup. 
Pale yellow liquid, yield 19.0 g, 76%; FT-IR (Paraffin) υ/cm-1: 3617, 2857, 1739; 1H NMR (400 MHz, 
DMSO-d6): δ = 4.56 (t, 1H, J = 4.8), 4.01 (q, 2 H, J = 7.2), 3.42 (d, 2 H, J = 5.2), 1.36-1.49 (m, 8 H), 
1.18 (t, 4 H, J = 7.2), 0.80 (t, 6 H, J = 8.6); MS (ES) m/z (m+1): 244.3 
 
4.3. General procedure for the synthesis of Ethyl-[2-n-butyl-2-hydroxy methyl]hexanoic acid (3) 
 
      To a stirred solution of ethyl-[2-n-butyl-2-hydroxymethyl]hexanoate (15.0 g, 0.0652 mol) in 
methanol (67.5 mL), was added NaOH (5.86 g, 0.146 mol) as a solution and the resulting mixture 
refluxed for 17 h. The methanol was distilled off at 55-60 oC under vacuum, cooled to room temperature 
and washed with petroleum ether. Aqueous layer was taken back to the reactor, cooled to 10-15 oC and 
acidified with concentrated HCl to pH 2. The mixture was extracted with dichloromethane (25 mL × 
2) and washed with brine solution. The organic layer was dried over sodium sulfate and concentrated 
under vacuum at 40 – 45 oC to yield a thick syrup. 
Pale yellow liquid, yield 13.73 g, 92%; FT-IR (Paraffin) υ/cm-1: 2857, 3359, 2857; 1H NMR (400 MHz, 
DMSO-d6): δ = 11.94 (s, 1 H), 3.40 (d, 2 H, J = 4.8), 1.34-1.46 (m, 8 H), 1.24 (t, 4 H, J = 7.2), 0.80 (t, 
6 H, J = 8.6); MS (ES) m/z (m+1): 203.3 
 
4.4. General procedure for the synthesis of 2-Bromomethyl-2-n-butylhexanoic acid (4)  
 
      To a solution of 48% (aq.) hydrobromic acid was added slowly concentrated H2SO4 below 25 oC 
over a period of 1 h and then added 2 (10 g, 0.049 mol). The reaction mixture was heated to 90-95 oC 
and maintained at this temperature for 16 h. The reaction was then cooled to 15-20 oC and extracted 
with dichloromethane (25 mL × 2). The organic layer was concentrated under vacuum at 40 – 45 oC, 
then the residue was distilled using a high vacuum pump. Product distilled at 140-160 oC/1 mm Hg. 
Pale yellow liquid, yield 4.36 g, 35%; FT-IR (Paraffin) υ/cm-1: 2857, 2923, 512; 1H NMR (400 MHz, 
DMSO-d6): δ = 12.62 (s, 1H), 3.58 (s, 1 H), 1.46-1.59 (m, 4 H), 1.19-1.28 (m, 8 H), 0.80 (t, 6 H, J = 
8.6); MS (ES) m/z (m+1): 266.2 
 
4.5. General procedure for the synthesis of 2-{[(2-Amino-5-methoxyphenyl)thio]methyl}-2-n-
butylhexanoic acid (6) 
 
      To a stirred solution of amino-6-methoxy benzothiazole (4.00 g, 0.022 mol) in water (44 mL) was 
added KOH (12.4 g, 0.22 mol). The reaction mixture was refluxed for 16 h under N2 atmosphere. It 
was then cooled to 15 oC and added 3 (7.63 g, 0.028 mol) in THF (9.48 mL) slowly over a period of 30 
min and then allowed the reaction mass to come to 20-25 oC and stirred for 10 h and then refluxed at 
60-65 oC for 2 h. It was then cooled to 20-25 oC and diluted with water. The reaction was then adjusted 
to pH 5 using 1.5 N HCl, diluted with water and extracted with DCM (25 mL × 2). The organic layer 
was washed with water and then with brine, dried over sodium sulfate and solvent was removed under 
reduced pressure to yield a thick syrup.  
 
       Dark brown liquid, yield 3.6 g, 90%; FT-IR (Paraffin) υ/cm-1: 3363, 3189, 2923, 2857; 1H NMR 
(400 MHz, DMSO-d6): δ = 6.83 (s, 1H), 6.64 (dd, 2 H, J = 2.8, 0.4), 3.60 (s, 3 H), 2.95 (s, 2 H), 1.48-
1.56 (m, 4 H), 1.13 (t, 4 H, J = 6.4), 1.20 (t, 4 H, J = 5.6), 0.80 (t, 6 H, J = 8.6); MS (ES) m/z (m+1): 
340.3 
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4.6. General procedure for the synthesis of 3,3-di-n-butyl-8-methoxy-2,3-dihydro-1,5-
benzothiazepin-4-(5H)-one (7): 
 
       To a stirred solution of 4 (3.00 g, 0.0088 mol) in ethyl acetate (27 mL), was added triethylamine 
(1.95 g, 0.0193 mol). The reaction mixture was cooled to 0 oC and T3P (2.81 g, 0.0088 mol) added at 
0 oC, then stirred at 25 oC for 3 h and diluted with ethyl acetate. The above organic layer was washed 
with 10% NaHCO3 solution, then water, brine, dried over sodium sulfate and concentrated under 
vacuum at 50 oC to obtain a crude product which was purified by chromatography on silica gel using 
ethyl acetate and hexane. 
Brown solid, yield 3.6 g, 90%; FT-IR (KBr) υ/cm-1: 3092, 2867, 1213, 1644; 1H NMR (400 MHz, 
DMSO-d6): δ = 9.48 (s, 1 H), 7.00 (d, 1 H, J = 8.4), 6.93 (d, 1 H, J = 2.8), 6.82 (q, 1 H, J = 2.8), 3.69 
(s, 3 H), 2.94 (s, 2 H), 1.39-1.46 (m, 4 H), 1.14-1.39 (m, 8 H), 0.80 (t, 6 H, J = 8.6); MS (ES) m/z 
(m+1): 322.0. 
 
4.7. General procedure for the synthesis of 3,3-Dibutyl-8-methoxy-5-alkyl-2,3-dihydro-5H-
benzo[b][1,4]thiazepin-4-one (8) 
 
       A solution of 5 (0.20 g, 0.62 mmol) in DMF (3 mL) was cooled to 0 oC under N2 atmosphere and 
NaH (0.0223g, 0.933 mmol) added and stirred for 15 min. To this reaction mixture, methyl iodide 
(0.0425 mL) was added and the reaction mixture allowed to stir for one hour at room temperature. 
Progress of the reaction was monitored by TLC. When the reaction was complete, the reaction mixture 
was diluted with water (30 mL) and extracted with ethyl acetate (25 mL × 2). The organic layer was 
dried over anhydrous sodium sulfate, and concentrated under vacuum to afford a crude product, which 
was purified by chromatography on silica gel using ethyl acetate and hexane. 
 
4.7.1. 3,3-Dibutyl-8-methoxy-5-methyl-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one (8a) 
 
       Colorless semi-solid, 1H NMR (400 MHz, DMSO-d6): δ = 7.30 (d, 1 H, J = 11.72), 7.10 (d, 1 H, J 
= 3.84), 7.03 (q, 1 H, J = 7.76, 3.88), 3.75 (s, 3 H), 3.17 (s, 3H), 3.00 (s, 2H), 1.06-1.34 (m, 12 H), 0.78 
(t, 3 H, J =8.6); MS (ES) m/z (m+1): 336.4 
4.7.2. 3,3-Dibutyl-5-ethyl-8-methoxy-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one (8b) 
Colorless semi-solid; 1H NMR (400 MHz, DMSO-d6): δ = 7.33 (d, 1 H, J = 8.8), 7.13 (d, 1 H, J = 2.96), 
7.03 (q, 1 H, J = 8.8, 3.00), 3.78 (s, 3 H), 3.01 (s, 2 H), 1.00-1.26 (m, 16 H), 0.78 (t, 6 H, J = 8.6); MS 
(ES) m/z (m+1): 350.4. 
 
4.7.3. 5-Allyl-3,3-dibutyl-8-methoxy-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one (8c) 
 
       Colorless semi-solid; 1H NMR (400 MHz, DMSO-d6): δ = 7.32 (d, 1 H, J = 8.8), 7.12 (d, 1 H, J = 
2.92), 7.04 (q, 1 H, J = 8.8, 2.96), 5.7-5.86 (m, 1 H), 5.14 (d, 1 H, J = 1.36), 5.10 (d, 1 H, J = 1.32), 
4.34 (s, 2 H), 3.77 (s, 3 H), 3.03 (s, 2 H), 1.32-1.37 (m, 12 H); MS (ES) m/z (m+1): 362.4. 
4.7.4. 3,3,5-Tributyl-8-methoxy-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one (8d) 
Colorless semi-solid 1H NMR (400 MHz, DMSO-d6): δ = 7.32 (d, 1 H, J = 8.8), 7.12 (d, 1 H, J = 2.8), 
7.03 (q, 1 H, J = 8.8, 2.40), 3.77 (s, 3 H), 3.00 (s, 2 H), 1.16-1.41 (m, 8 H), 1.04-1.16 (m, 9 H), 0.85 (t, 
9 H, J = 5.6); MS (ES) m/z (m+1): 378.4. 
 
4.7.5. 3,3-Dibutyl-5-isobutyl-8-methoxy-2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one (8e) 
 
       Colorless semi-solid 1H NMR (400 MHz, DMSO-d6): δ = 7.34 (d, 1 H, J = 8.8), 7.13 (d, 1 H, J = 
2.96), 7.04 (q, 1 H, J = 8.8, 3.0), 3.77 (s, 3 H), 3.04 (s, 2 H), 1.77 (m, 1 H); MS (ES) m/z (m+1): 378.3. 
 
4.7.6. 2-(3,3-Dibutyl-8-methoxy-4-oxo-3,4-dihydro-2H-benzo[b][1,4]thiazepin-5-yl)-N-isopropyl-
acetamide (8f) 
 
 
Off-white solid 1H NMR (400 MHz, DMSO-d6): δ = 7.66 (d, 1 H, J = 7.2), 7.42 (d, 1 H, J = 8.8), 7.03 
(q, 1 H, J = 8.8, 3.2), 3.8 (m, 1 H), 3.76 (s, 3 H), 3.03 (s, 2 H), 1.22-1.34 (m, 14 H), 1.00 (d, 6 H, J = 
6.4), 0.77 (t, 6 H, J = 5.6); MS (ES) m/z (m+1): 421.4. 
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4.7.7. 3,3-Dibutyl-8-methoxy-5(2-piperidin-1-yl-ethyl)2,3-dihydro-5H-benzo[b][1,4]thiazepin-4-one 
(8g) 
 
      Yellow semi-solid 1H NMR (400 MHz, DMSO-d6): δ = 7.55 (d, 1 H, J = 11.72), 7.08 (d, 1 H, J = 
3.76), 7.04 (q, 1 H, J = 7.8, 3.8), 3.75 (s, 3 H), 2.97 (s, 2 H), 2.25 (m, 4 H), 1.01-1.40 (m, 26 H), 0.77 
(t, 6 H, J = 5.6); MS (ES) m/z (m+1): 433.4.  
 
4.8. Antioxidant activities 
 
4.8.1.  DPPH radical scavenging assay 
 
      DPPH radical scavenging activity was carried out according to the method of Scherer et al..32 
Briefly, DPPH solution (1 mL, 0.1 mM in 95% ethanol) was mixed with different aliquots of 8a-8g. 
After vigorous shaking, the mixture was allowed to stand for 20 min at room temperature. Absorbance 
of the resulting solution was measured at 517 nm with a UV-VIS spectrophotometer (HITACHI, U-
2900). Butylated hydroxyl toluene (BHT) was used as positive control. Radical scavenging potential is 
expressed as IC50 value, which represents the sample concentration at which 50 % of DPPH radicals 
are scavenged. 
 
4.8.2. Hydroxyl radical scavenging assay  
 
      The reaction mixture containing different aliquots of 8a-8g, deoxyribose (10 mM), H2O2 (10 mM), 
FeCl3 (5 mM), EDTA (1 mM) and ascorbic acid (5 mM) in potassium phosphate buffer (50 mM, pH 
7.4) was allowed to stand for 60 min at 37 oC.33 The reaction was terminated by adding TCA (5% W/V) 
and the reaction product was measured by reaction with TBA (0.2% W/V) in boiling water bath for 15 
min. The absorbance was measured at 535 nm against the reagent blank and inhibition of the oxidation 
of deoxyribose was calculated against the control using UV-VIS spectrophotometer (HITACHI, U-
2900). BHT was used as positive control and radical scavenging potential was expressed as IC50 value. 
 
4.8.3. Nitric oxide radical scavenging activity 
 
      Nitric oxide was generated from sodium nitroprusside and measured by Griess reaction. Sodium 
nitroprusside in phosphate buffer at physiological pH spontaneously generates nitric oxide, which in 
turn reacts with oxygen to produce nitrite ions that can be estimated by the Griess reagent.34 Nitric 
oxide scavengers compete with oxygen, leading to reduced production of nitric oxide. Sodium 
nitroprusside (5 mM) in phosphate buffered saline was mixed with different aliquots of 8a-8g and 
incubated at 25 ºC for 3 h. The absorbance of the color formed during the diazotization of nitrite with 
sulphanilamide and subsequent coupling with napthylethylenediamine was read at 546 nm and referred 
with the absorbance of BHT treated in the same way with the Griess reagent. The radical scavenging 
potential was calculated and expressed as IC50 value. 
 
4.8.4. Ferrous ion chelating ability 
 
      Ferrous ion chelating ability was measured according to the method of Suter and Richter.35 Three 
sets of test tubes were taken; the first tube as control: To this 40 µL of FeCl3 (200 µM) and 80 µL of 
K3Fe(CN)6 (400 mM ) were added and the volume was made up to 1 mL by adding distilled water. For 
the second tube 20 µL of EDTA (400 mM), 40 mL of FeCl3 and 80 µL K3Fe(CN)6 were added and the 
volume was made up to 1 mL by adding distilled water. For the third sample (10 µg-100 µg), 40 µL of 
FeCl3 and 80 µL of K3Fe(CN)6 were added and the volume was made up to 1 mL by adding distilled 
water. The tubes were incubated for 10 min at 20 oC and the OD read at 700 nm. The assay was carried 
out at 20 oC to prevent Fe2+ oxidation. 
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4.9.  Antiangiogenic activity 
    
      Fertilized eggs were obtained from IVRI, Bangalore, India. All chemicals were purchased from 
Sisco Research Laboratories, Mumbai, India and they were of analytical grade. Antiangiogenic effects 
of 8a-8g compounds was studied according to the method of Auerbach et al.36. Briefly, fertilized hens 
eggs were surface sterilized using 70% alcohol. The eggs were incubated in fan assisted humidified 
incubator at 37 ºC. On the 4th day, the eggs were cracked out into thin films of the hammock within a 
laminar flow cabinet and were further incubated. On day 5th when blood vessels were seen proliferating 
from the center of the eggs within the hammock, filter paper discs loaded with 100 µg of the compounds 
8a-8g were placed over the proliferating blood vessels and the eggs were returned to the incubator. 
Results of antiangiogenic effects of the compounds were noted after 24 h. 
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